Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
New York State Psychiatric Institute
This pilot study will recruit 40 patients with Major Depression and a history of at least two failed prior adequate somatic treatments. In addition to usual physical work-up, all patients will have extensive thyroid testing, and then will receive standard dose Tranylcypromine (i.e., max. 60 mg/d). Non-remitters will have dose increased to max. 120 mg/d if tolerated. Non-remitters to high dose Tranylcypromine will then have Dextroamphetamine added with frequent blood pressure monitoring to max. 40 mg/d. Non-remitters will have Triiodothyronine added to the Tranylcypromine.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Ages between 18-65
Major Depression
At least two prior ineffective antidepressant trials (at least 2 different mechanisms) or 1 inadequate ECT trial (at least 8 bilateral treatments)
Physically healthy
You may not be if
Known Tranylcypromine allergy
Unable to follow tyramine-free diet
Known allergy, intolerance or prior addiction to any stimulant would preclude patient's inclusion in the Dextroamphetamine portion of the protocol
Current substance use disorder including alcohol)(past six months); ever dependent on stimulants would preclude Dextroamphetamine portion of the protocol
Unable or unwilling to discontinue antidepressants including OTC antidepressants such as St. John's Wort
History of psychosis, such as schizophrenia or psychotic depression; history of bipolar mania will be allowed if on adequate mood stabilizer
Suicidal ideation/activity that makes outpatient treatment unsafe, unless protocol can be conducted as inpatient
Current systolic BP \> 149 or diastolic BP \> 89 mm Hg (two readings); adequately treated hypertension is acceptable
Evidence of hypo- or hyperthyroidism
Pregnancy, lactation, refusal to use adequate birth control